Shandong Tianming Pharmaceutical, a GMP-certified leader in advanced API and intermediate manufacturing, will unveil its latest innovations at CPHI China 2025 (June 24-26, Shanghai New International Expo Centre).
Visit us at Booth W2G30 to explore cutting-edge solutions reshaping pharmaceutical synthesis.
As an eight-time exhibitor with proven industry partnerships, we deliver more than products – we offer actionable pathways to:
1/Explore cutting-edge API synthesis technology and break through R&D bottlenecks
2/Unlock customized solutions:
3/Overcome Regulatory Hurdles
4/Global compliance escort, opening up international market access channels
– GLP-1 Agonist Intermediates: >99.9% chiral purity for obesity/diabetes pipelines
– Antibiotic Resistance Fighters: β-lactamase inhibitor scaffolds with 80% oral bioavailability
– On-Demand Synthesis: From R&D samples to commercial batches
With 300+ commercial APIs and 15 years of GMP excellence, Tianming enables partners across 40 countries to overcome synthesis scalability, compliance, and sustainability challenges.
We look forward to seeing you at CPHI China 2025!
Best regards
Sales Team
Shandong Tianming Pharmaceutical Group
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.
Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.